Biostar Pharmaceuticals, Inc.

BSPM

US0906783016

Pharmaceuticals

Delayed OTC Markets Other stock markets 01:12:37 24/04/2024 am IST			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI
2023	Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	CI

Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016

April 14, 2017 at 01:30 am IST

Biostar Pharmaceuticals, Inc. reported consolidated earnings results for the year ended December 31, 2016. For the year, the company's sales, net were USD 2,384,492 compared to USD 27,129,609 a year ago. Loss from operations was USD 3,564,262 compared to USD 23,757,564 a year ago. Loss before income taxes was USD 3,045,331 compared to USD 23,792,716 a year ago. Net loss was USD 5,698,385 compared to USD 25,112,562 a year ago. Basic and diluted loss per share was USD 2.5 compared to USD 11.4 a year ago. Net cash provided by operating activities was USD 4,912,665 compared to USD 5,877,213 a year ago.

Latest news about Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	15/23/15	CI
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	12/23/12	CI
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.	02/19/02	CI
Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index	18/18/18	CI
Waiping Liu Discloses its Plans on Biostar Pharmaceuticals	03/18/03	CI
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.	02/18/02	CI
Biostar Pharmaceuticals, Inc. Announces Board Changes	03/18/03	CI
Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee	29/17/29	CI
Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director	19/17/19	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	21/17/21	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	16/17/16	CI
Biostar Pharmaceuticals Seeks Acquisitions	15/17/15	CI
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd.	07/17/07	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	20/17/20	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016	14/17/14	CI
Biostar Pharmaceuticals, Inc. Announces Management Changes	10/17/10	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	22/16/22	CI
Biostar Pharmaceuticals, Inc. to Launch New Product Aimed at Treating Effects of Rhinitis and Sinusitis	11/16/11	CI
Biostar Pharmaceuticals, Inc. executed a non-binding letter of intent to acquire Xianyang Yongsheng Health Products Co., Ltd.	22/16/22	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	23/16/23	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016	24/16/24	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2015	15/16/15	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2015	24/15/24	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results of the Second Quarter and Six Months Ended June 30, 2015	20/15/20	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	16/15/16	CI

Chart Biostar Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People's Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company's products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company's products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOSTAR PHARMACEUTICALS, INC.	-.--%	263
NOVO NORDISK A/S	+31.37%	59TCr
JOHNSON & JOHNSON	-2.79%	36TCr
MERCK & CO., INC.	+20.48%	33TCr
ABBVIE INC.	+5.49%	29TCr
ASTRAZENECA PLC	+14.83%	24TCr
NOVARTIS AG	+9.93%	21TCr
ROCHE HOLDING AG	-6.95%	20TCr
AMGEN INC.	+10.82%	17TCr
PFIZER, INC.	+0.14%	16TCr

Other Pharmaceuticals